CombinatoRx, Incorporated (NASDAQ: CRXX) is seeing its stock implode this morning. The company released data from its Phase IIb study of Synavive (CRx-102) for knee osteoarthritis showing that its Synavive test was not statistically significant. This is likely more than just a setback for the Synavive program, but CombinatoRx said it will continue to evaluate and analyze the data.
Shareholders and traders alike are firing first and asking questions later. Shares closed at $3.00 Friday and its 52-week trading range was $2.86 to $6.99. Its pre-market stock trading indications are down nearly 60% at $1.25.
Jon C. Ogg
October 6, 2008
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
